Status:
COMPLETED
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER). Dialogues Time to Talk Program is a patient manage...
Eligibility Criteria
Inclusion
- Currently experiencing a major depressive episode, which requires the initiation of antidepressant drug treatment or a change in current antidepressant drug treatment
- At least 18 years of age
Exclusion
- History or presence of bipolar disorder
- Current treatment with venlafaxine
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
537 Patients enrolled
Trial Details
Trial ID
NCT00401726
Start Date
June 1 2006
End Date
October 1 2007
Last Update
April 23 2012
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35216
2
Birmingham, Alabama, United States, 35235
3
Mesa, Arizona, United States, 85206
4
Little Rock, Arkansas, United States, 72211